

Benjamin Daniels

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1733387/publications.pdf>

Version: 2024-02-01

39
papers

718
citations

623188

14
h-index

552369

26
g-index

42
all docs

42
docs citations

42
times ranked

1329
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of tightened prescribing restrictions on proton pump inhibitor use in Australia: An evaluation using interrupted time series analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 370-378.	0.9	0
2	Long-term trajectories of medicine use among older adults experiencing polypharmacy in Australia. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1264-1274.	1.1	14
3	A cross sectional study of psychotropic medicine use in Australia in 2018: A focus on polypharmacy. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1369-1377.	1.1	12
4	Patterns of oxycodone controlled release use in older people with cancer following public subsidy of oxycodone/naloxone formulations: An Australian population-based study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 68-78.	0.7	2
5	Coming to grips with seemingly conflicting results in programme evaluation: the devil's in the detail. <i>BMJ Quality and Safety</i> , 2021, 30, 70-71.	1.8	1
6	Real-world data to advance HER2-targeted cancer medicines research: Playing to the strengths of clinical registry and administrative data. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 414-415.	0.7	0
7	Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 893-902.	1.1	2
8	Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort. <i>Breast</i> , 2021, 58, 106-112.	0.9	6
9	Changes in systemic cancer therapy in Australia during the COVID-19 pandemic: a population-based study. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 14, 100226.	1.3	11
10	Comparison of claims from high drug cost beneficiaries in Ontario, Canada, and Australia: a cross-sectional analysis. <i>CMAJ Open</i> , 2021, 9, E1048-E1054.	1.1	0
11	Medicine treatment of glaucoma in Australia 2012-2019: prevalence, incidence and persistence. <i>BMJ Open Ophthalmology</i> , 2021, 6, e000921.	0.8	1
12	A national study on prescribed medicine use in Australia on a typical day. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1046-1053.	0.9	18
13	ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target. <i>Scientific Reports</i> , 2020, 10, 13906.	1.6	17
14	Impact of NPS MedicineWise general practitioner education programs and Choosing Wisely Australia recommendations on prescribing of proton pump inhibitors in Australia. <i>BMC Family Practice</i> , 2020, 21, 85.	2.9	7
15	Potentially inappropriate benzodiazepine use in Australian adults: A population-based study (2014-2017). <i>Drug and Alcohol Review</i> , 2020, 39, 575-582.	1.1	8
16	Passing the acid test? Evaluating the impact of national education initiatives to reduce proton pump inhibitor use in Australia. <i>BMJ Quality and Safety</i> , 2020, 29, 365-373.	1.8	12
17	Risk of squamous cell carcinoma of the lip and cutaneous melanoma in older Australians using hydrochlorothiazide: A population-based case-control study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 127, 320-328.	1.2	23
18	Long-term use of proton-pump inhibitors: whole-of-population patterns in Australia 2013-2016. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482091374.	1.4	30

#	ARTICLE	IF	CITATIONS
19	Identifying incident cancer cases in dispensing claims. <i>International Journal of Population Data Science</i> , 2020, 5, 1152.	0.1	1
20	Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003â€“2015). <i>BMC Cancer</i> , 2019, 19, 909.	1.1	7
21	Metastatic breast cancer incidence, site and survival in Australia, 2001â€“2016: a population-based health record linkage study protocol. <i>BMJ Open</i> , 2019, 9, e026414.	0.8	17
22	Patterns of endocrine therapy in a national cohort of early stage HER2â€­positive breast cancer patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 812-820.	0.9	7
23	Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007â€“2016). <i>British Journal of Cancer</i> , 2019, 121, 904-911.	2.9	9
24	Predictors of care for patients with cancer of unknown primary site in three Australian hospitals. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e512-e520.	0.7	2
25	Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001â€“2016). <i>Breast</i> , 2018, 38, 7-13.	0.9	23
26	Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006â€“2014). <i>British Journal of Cancer</i> , 2018, 118, 441-447.	2.9	13
27	Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001â€“2016). <i>Breast Cancer Research and Treatment</i> , 2018, 171, 151-159.	1.1	20
28	Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016). <i>PLoS ONE</i> , 2018, 13, e0198152.	1.1	4
29	Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort. <i>BMJ Open</i> , 2017, 7, e014439.	0.8	15
30	Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposure. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 990-999.	1.3	51
31	Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2581-2588.	1.1	28
32	Validation of specificity of antibodies for immunohistochemistry: the case of ROR2. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 99-108.	1.4	13
33	Retrospective comparison of Australiaâ€™s Pharmaceutical Benefits Scheme claims data with prescription data in HER2-positive early breast cancer patients, 2008â€“2012. <i>Public Health Research and Practice</i> , 2017, 27, .	0.7	3
34	ADHD medication overdose and misuse: the NSW Poisons Information Centre experience, 2004â€“2014. <i>Medical Journal of Australia</i> , 2016, 204, 154-154.	0.8	21
35	Second Cancer Risk and Late Mortality in Adult Australians Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Population-Based Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 949-956.	2.0	26
36	Looking forward and looking back: the balancing act in new drug user designs for pharmacoepidemiological research. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 1117-1119.	0.9	5

#	ARTICLE	IF	CITATIONS
37	Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β^2 -catenin dependent and independent Wnt signalling. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 243-254.	1.2	58
38	Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis. <i>Acta Neuropathologica Communications</i> , 2014, 2, 9.	2.4	138
39	A Metabolic Shift Favoring Sphingosine 1-Phosphate at the Expense of Ceramide Controls Glioblastoma Angiogenesis. <i>Journal of Biological Chemistry</i> , 2013, 288, 37355-37364.	1.6	90